In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Regeneron’s current price is 32.6% below its high-confidence PERT-weighted fair value, indicating potential undervaluation supported by strong DCF results. Financial health scores are excellent, reflecting robust liquidity and growth. However, Monte Carlo simulation reveals high volatility (107.72% CV) and 23.5% downside risk below the current price, signaling notable valuation variability.